Atherosclerosis

Reflection Magnitude as a Predictor of Mortality: The Multi-Ethnic Study of Atherosclerosis.

Zamani P1, Jacobs DR Jr2, Segers P2, Duprez DA2, Brumback L2, Kronmal RA2, Lilly SM2, Townsend RR2, Budoff M2, Lima JA2, Hannan P2, Chirinos JA2.

Abstract
Arterial wave reflections have been associated with mortality in an ethnically homogenous Asian population. It is unknown whether this association is present in a multiethnic population or whether it is independent of subclinical atherosclerosis. We hypothesized that reflection magnitude (defined as the ratio of the amplitude of the backward wave [Pb] to that of the forward wave [Pf]) is associated with all-cause mortality in a large multiethnic adult community-based sample. We studied 5984 participants enrolled in the Multi-Ethnic Study of Atherosclerosis who had analyzable arterial tonometry waveforms. During 9.8±1.7 years of follow-up, 617 deaths occurred, of which 134 (22%) were adjudicated cardiovascular deaths. In Cox proportional hazards models, each 10% increase in reflection magnitude was associated with a 31% increased risk for all-cause mortality (hazard ratio [HR]=1.31; 95% confidence interval [CI]=1.11-1.55; P=0.001). This relationship persisted after adjustment for various confounders and for markers of subclinical atherosclerosis (HR=1.23; 95% CI=1.01-1.51; P=0.04), including the coronary calcium score, ankle-brachial index, common carotid intima-media thickness, and ascending thoracic aortic Agatston score. Pb was independently associated with all-cause mortality in a similarly adjusted model (HR per 10 mm Hg increase in Pb=2.18; 95% CI=1.21-3.92; P=0.009). Reflection magnitude (HR=1.71; 95% CI=1.06-2.77; P=0.03) and Pb (HR=5.02; 95% CI=1.29-19.42; P=0.02) were mainly associated with cardiovascular mortality. In conclusion, reflection magnitude is independently associated with all-cause mortality in a multiethnic population initially free of clinically evident cardiovascular disease. This relationship persists after adjustment for a comprehensive set of markers of subclinical atherosclerosis.
© 2014 American Heart Association, Inc.PMID: 25259746 [PubMed - as supplied by publisher]

:: Courtesy NCBI (National Center for Biotechnology Information) Database and The NIH (National Institutes of Health) ::​

http://www.ncbi.nlm.nih.gov/pubmed/25259746
http://www.ncbi.nlm.nih.gov/pubmed/24882580
http://www.ncbi.nlm.nih.gov/pubmed/24884546
http://www.ncbi.nlm.nih.gov/pubmed/24653700


The following product(s) are being used for the research of the above disease, illness or condition
Visfatin Human

Visfatin Human Recombinant

5µg - ($ 50)
25µg - ($ 130)
1mg - ($ 2700)
Qty
Visfatin Mouse

Visfatin Mouse Recombinant

5µg - ($ 50)
25µg - ($ 130)
1mg - ($ 3600)
Qty
IL 3 Human

Interleukin-3 Human Recombinant

2µg - ($ 50)
10µg - ($ 130)
1mg - ($ 2700)
Qty
IL 6 Mouse

Interleukin-6 Mouse Recombinant

2µg - ($ 50)
10µg - ($ 130)
1mg - ($ 2700)
Qty
PDGF A Human

Platelet-Derived Growth Factor A Human Recombinant

5µg - ($ 50)
20µg - ($ 130)
1mg - ($ 2600)
Qty
PDGF AB Human

Platelet-Derived Growth Factor AB Human Recombinant

2µg - ($ 50)
10µg - ($ 130)
1mg - ($ 3510)
Qty
PDGF B Human

Platelet-Derived Growth Factor B Human Recombinant

5µg - ($ 50)
20µg - ($ 130)
1mg - ($ 2600)
Qty
CST3 Human

Cystatin-C Human

20µg - ($ 50)
100µg - ($ 130)
1mg - ($ 1400)
Qty
HDL Human

High Density Lipoprotein Human

10mg - ($ 130)
100mg - ($ 600)
1gram - ($ 5000)
Qty
FABP4 Human

Fatty Acid Binding Protein 4 Human Recombinant

2µg - ($ 50)
10µg - ($ 130)
1mg - ($ 3600)
Qty
CST3 Rat

Cystatin C Rat Recombinant

2µg - ($ 50)
10µg - ($ 130)
1mg - ($ 5200)
Qty
Visfatin Human, His

Visfatin Recombinant Human, His Tag

5µg - ($ 50)
25µg - ($ 130)
1mg - ($ 4500)
Qty
CD62E Antibody

E-Selectin, Mouse Anti-Human

500µg - ($ 155)
1mg - ($ 290)
Qty
FABP4 Human, His

Fatty Acid Binding Protein 4 Human Recombinant, His Tag

5µg - ($ 50)
25µg - ($ 130)
1mg - ($ 2500)
Qty
HMOX1 Human

Heme Oxygenase 1 Human Recombinant

10µg - ($ 50)
50µg - ($ 130)
1mg - ($ 1800)
Qty
PLA2G7 Human

Secreted Phospholipase A2-VII Human Recombinant

5µg - ($ 50)
20µg - ($ 130)
1mg - ($ 2700)
Qty
Visfatin Antibody

Visfatin, Mouse Anti Human

5µg - ($ 50)
20µg - ($ 130)
100µg - ($ 450)
Qty
SAA4 Human

Serum Amyloid A4 Human Recombinant

2µg - ($ 50)
10µg - ($ 130)
1mg - ($ 5200)
Qty
CST3 k9

Cystatin-C Canine Recombinant

2µg - ($ 50)
10µg - ($ 130)
1mg - ($ 5200)
Qty
LPL Human

Lipoprotein Lipase Human Recombinant

2µg - ($ 50)
10µg - ($ 130)
1mg - ($ 5200)
Qty
LPL Human, HEK

Lipoprotein Lipase Human Recombinant, HEK

2µg - ($ 50)
10µg - ($ 130)
1mg - ($ 5200)
Qty
Chlamydia Pneumonia

Chlamydia Pneumonia Recombinant

100µg - ($ 150)
500µg - ($ 600)
1000µg - ($ 1200)
Qty
CST3 Human, Active

Cystatin-C Human Recombinant, Active

2µg - ($ 50)
10µg - ($ 130)
1mg - ($ 5200)
Qty
NCEH1 Human

Neutral Cholesterol Ester Hydrolase 1 Human Recombinant

5µg - ($ 50)
20µg - ($ 130)
1mg - ($ 2700)
Qty
CEL Human

Carboxyl Ester Lipase Human

2µg - ($ 50)
10µg - ($ 130)
100µg - ($ 1200)
Qty

Note:

BioInfoMedical is a leading global provider of products and services used in gene, protein and cell research, drug discovery and development, biopharmaceutical manufacturing and transfer of new technologies.

BioInfoMedical specializes in satisfying customers demand for high quality cytokine products including E. coli, insect, and mammalian cell-derived recombinant proteins, monoclonal/polyclonal antibodies, and other cytokine-related reagents.

The specific products and services, offered by BioInfoMedical Biotechnology, range from cytokines and related molecules (such as interleukins, growth factors, chemokines), adhesion molecules, neurotrophic factors, proteases, receptors, developmental proteins, apoptosis and signal transduction-related molecules, and full Technology-License packages with a comprehensive course at ours/customers lab facility. Diagnostic tests are also available in broad spectrum of diseases - Staph, Strep, Malaria, Typhoid, Sexually Transmitted Diseases, Cholera, autoimmune diseases, and diseases like Atherosclerosis described on this page..

Please contact us with any questions or inquiries regarding our above stated goals. We will continue to update and improve on this website to meet the needs of You, our customers and to further the larger, global need for disease research and ultimate cures.